‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 
Today's Geriatric Medicine
E-Newsletter    August 2022
Facebook Twitter

Editor's E-Note

Effective treatments for gastroparesis—the delayed gastric emptying of solid food not caused by a mechanical obstruction—are greatly needed to reduce mortality and improve quality of life. There’s only one pharmaceutical treatment for the disorder, and it’s approved only for diabetic gastroparesis, not other types. Processa Pharmaceuticals is conducting a Phase 2 clinical trial of a “highly selective 5-hydroxytryptamine-4 receptor agonist.”

In addition to reading our e-newsletter, be sure to visit Today’s Geriatric Medicine’s website at www.TodaysGeriatricMedicine.com, where you’ll find news and information that’s relevant and reliable. We welcome your feedback at TGMeditor@gvpub.com. Follow Today’s Geriatric Medicine on Facebook and Twitter, too.

— Kate Jackson, editor
In This E-Newsletter

E-News Exclusive
A Phase 2 Clinical Trial of a Drug for Gastroparesis

Processa Pharmaceuticals, a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need, recently announced that it has enrolled its first patient in the Phase 2A clinical trial of PCS12852 in patients with moderate to severe gastroparesis. Gastroparesis is a chronic gastric motility disorder in which the stomach does not empty food as quickly as it should, resulting in potentially serious forms of heartburn, nausea, vomiting, and bloating for millions of patients in the United States. As such gastroparesis is recognized to be a serious unmet medical need condition for which patients need alternative treatment options.

Currently, the only FDA-approved pharmaceutical treatment for gastroparesis is metoclopramide, a dopamine D2 receptor antagonist, which is approved only for diabetic gastroparesis, not for other subsets of gastroparesis. Additionally, it carries a black box warning, limiting use for this chronic disorder to less than 12 weeks due to potentially serious side effects.

Recently in Today's Geriatric Medicine
The Gut-Endocannabinoid Axis
The link between the two systems has far-reaching implications. Read more »

The Pros and Cons of Coffee Consumption for Older Adults
There’s long been a debate over whether drinking coffee at older ages is healthy. Here’s a look at what the studies say about grabbing that cup of joe in the morning. Read more »
Other Geriatric News
A Study in Antiaging
According to research published in Science, the study of centenarian tortoises and turtles that live relatively free from the limitations and physical insults of aging “may hold insights for prolonging longevity and decreasing age-related decline,” The New York Times reports.

Unpleasant Patients
Do you have patients you don’t like? You’re not alone. According to a new study in the Annals of Internal Medicine, many health care professionals admit to being frustrated by certain patients (as many as 15%) to a degree that affects quality of care. But, according to an article in The Washington Post, there are strategies that can help.

An Unlevel Playing Field
Black residents leave or are forced out of training programs at much greater rates than white residents, preventing them from entering and excelling in certain specialties, according to a STAT investigation.

An Added Benefit of the Flu Vaccine
A study from UTHealth Houston reveals that the influenza virus has an influence on the development of Alzheimer’s disease. Science Daily reports that researchers found that flu vaccines decrease the risk of developing the disease, and the benefit increases with the number of years of vaccination.
Products & Services
Help Navigating the 21st Century Cures Act
Greenway Health has launched Greenway’s 21st Century Cures Academy—a resource center for providers negotiating the legal requirements and understanding the industry effects of the 21st Century Cures Act. It’s a free resource available to anyone wanting to learn more. It provides materials including checklists, quick guides, webinars, and other resources to assist health care providers. Learn more »

A New Platform for Gastrointestinal Health
GIThrive, from Vivante Health, is the first comprehensive digital health platform designed specifically to address gastrointestinal health issues. It combines gut bacteria analysis and trigger food identification with app-based personalized action plans, food diaries, educational materials, and 24/7 support from experts. Learn more »
Current Issue
Differences in Women’s Heart Health
There still seems to be a lack of awareness in regard to women’s heart health, resulting in disparities in the treatment of cardiovascular disease.

Diminished Appetite at End of Life
For terminally ill patients, decreased appetite is normal and expected, so providers should ensure that feedings are not causing patients discomfort.

Advertising Opportunities
Have a product or service you want to market to geriatric care professionals? Utilize the reach of Today's Geriatric Medicine Magazine to accomplish your marketing goals. Email our experienced account executives today at sales@gvpub.com or call 800-278-4400 for more information.

Facebook Twitter
© 2022 Today's Geriatric Medicine Magazine